These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 34105307)

  • 1. Clinical and Methodologic Considerations With Regard to a Trial of Nintedanib in Patients With Systemic Sclerosis-Associated Interstitial Lung Disease: Comment on the Reanalysis by Maher et al.
    Bredemeier M
    Arthritis Rheumatol; 2021 Dec; 73(12):2353-2354. PubMed ID: 34105307
    [No Abstract]   [Full Text] [Related]  

  • 2. A new therapy for systemic sclerosis-associated interstitial lung disease.
    Kondoh Y
    Respir Investig; 2020 Jul; 58(4):227-229. PubMed ID: 32451295
    [No Abstract]   [Full Text] [Related]  

  • 3. Nintedanib for systemic sclerosis-associated interstitial lung disease.
    Rahimi S
    Lancet Respir Med; 2020 Feb; 8(2):136. PubMed ID: 31932219
    [No Abstract]   [Full Text] [Related]  

  • 4. Nintedanib for Systemic Sclerosis-Associated Interstitial Lung Disease.
    Distler O; Highland KB; Gahlemann M; Azuma A; Fischer A; Mayes MD; Raghu G; Sauter W; Girard M; Alves M; Clerisme-Beaty E; Stowasser S; Tetzlaff K; Kuwana M; Maher TM;
    N Engl J Med; 2019 Jun; 380(26):2518-2528. PubMed ID: 31112379
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and safety of nintedanib in patients with systemic sclerosis-associated interstitial lung disease treated with mycophenolate: a subgroup analysis of the SENSCIS trial.
    Highland KB; Distler O; Kuwana M; Allanore Y; Assassi S; Azuma A; Bourdin A; Denton CP; Distler JHW; Hoffmann-Vold AM; Khanna D; Mayes MD; Raghu G; Vonk MC; Gahlemann M; Clerisme-Beaty E; Girard M; Stowasser S; Zoz D; Maher TM;
    Lancet Respir Med; 2021 Jan; 9(1):96-106. PubMed ID: 33412120
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Nintedanib: New indication for systemic sclerosis-associated interstitial lung disease.
    Kuwana M; Azuma A
    Mod Rheumatol; 2020 Mar; 30(2):225-231. PubMed ID: 31747840
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Correspondence on 'Safety and tolerability of nintedanib in patients with systemic sclerosis-associated interstitial lung disease: data from the SENSCIS trial'.
    Bredemeier M
    Ann Rheum Dis; 2022 Dec; 81(12):e250. PubMed ID: 33023963
    [No Abstract]   [Full Text] [Related]  

  • 8. Novel Therapeutic Approaches for Pulmonary Manifestations of Systemic Sclerosis.
    Lui JK; Bosch NA; Gillmeyer KR; Reardon CC
    Am J Respir Crit Care Med; 2020 Sep; 202(6):878-880. PubMed ID: 32574505
    [No Abstract]   [Full Text] [Related]  

  • 9. Response to: 'Correspondence on 'Safety and tolerability of nintedanib in patients with systemic sclerosis-associated interstitial lung disease: data from the SENSCIS trial'' by Bredemeier.
    Seibold JR; Kohlbrenner V; Alves M; Distler O
    Ann Rheum Dis; 2022 Dec; 81(12):e251. PubMed ID: 33023957
    [No Abstract]   [Full Text] [Related]  

  • 10. Design of a randomised, placebo-controlled clinical trial of nintedanib in patients with systemic sclerosis-associated interstitial lung disease (SENSCIS™).
    Distler O; Brown KK; Distler JHW; Assassi S; Maher TM; Cottin V; Varga J; Coeck C; Gahlemann M; Sauter W; Schmidt H; Highland KB;
    Clin Exp Rheumatol; 2017; 35 Suppl 106(4):75-81. PubMed ID: 28664834
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Additional points to consider before incorporating the Food and Drug Administration-approved therapies for systemic sclerosis-associated interstitial lung disease: comment on the article by Khanna et al.
    Bredemeier M
    Arthritis Rheumatol; 2022 Apr; 74(4):733-734. PubMed ID: 34612018
    [No Abstract]   [Full Text] [Related]  

  • 12. Comment on: Anti-acid therapy in SSc-associated interstitial lung disease: long-term outcomes from the German Network for Systemic Sclerosis.
    Moran-Mendoza O; Al-Jarallah A; Alqahtani S; Paredes C
    Rheumatology (Oxford); 2023 Dec; 62(12):e349-e350. PubMed ID: 37369016
    [No Abstract]   [Full Text] [Related]  

  • 13. [How do I treat interstitial lung disease in systemic sclerosis?].
    Riemekasten G
    Z Rheumatol; 2021 Feb; 80(1):69-72. PubMed ID: 33340058
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antifibrotic efficacy of nintedanib in a cellular model of systemic sclerosis-associated interstitial lung disease.
    Atanelishvili I; Akter T; Noguchi A; Vuyiv O; Wollin L; Silver RM; Bogatkevich GS
    Clin Exp Rheumatol; 2019; 37 Suppl 119(4):115-124. PubMed ID: 31573469
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Nintedanib in systemic sclerosis treatment: a case report.
    Kudsi M; Tarcha R; Khalayli N
    J Med Case Rep; 2024 Feb; 18(1):110. PubMed ID: 38388392
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comment on: Anti-acid therapy in SSc-associated interstitial lung disease: long-term outcomes from the German Network for Systemic Sclerosis-caution is key in interpreting retrospective data: Reply.
    Kreuter M; Bonella F; Moinzadeh P; Hunzelmann N
    Rheumatology (Oxford); 2023 Dec; 62(12):e351-e352. PubMed ID: 37369015
    [No Abstract]   [Full Text] [Related]  

  • 17. Nintedanib for the treatment of systemic sclerosis-associated interstitial lung disease.
    Yamasaki Y; Kuwana M
    Expert Rev Clin Immunol; 2020 Jun; 16(6):547-560. PubMed ID: 32506975
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Nintedanib in patients with systemic sclerosis-associated interstitial lung disease: A Japanese population analysis of the SENSCIS trial.
    Kuwana M; Ogura T; Makino S; Homma S; Kondoh Y; Saito A; Ugai H; Gahlemann M; Takehara K; Azuma A
    Mod Rheumatol; 2021 Jan; 31(1):141-150. PubMed ID: 32243207
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Relevance of immunomodulatory therapy for interstitial lung disease in systemic sclerosis.
    Aringer M; Riemekasten G
    Best Pract Res Clin Rheumatol; 2021 Sep; 35(3):101672. PubMed ID: 33745826
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Anti-fibrotic nintedanib-a new opportunity for systemic sclerosis patients?
    Duarte AC; Santos MJ; Cordeiro A
    Clin Rheumatol; 2018 Apr; 37(4):1123-1127. PubMed ID: 29038968
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.